New Zealand's Pharmac has announced it will fund Eisai's LENVIMA (lenvatinib) from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer.
Pharmac makes cancer therapy the 26th funded since budget boost
November 11, 2024 BioPharmaLatest News
Latest Video
New Stories
-
Australia can increase prices in response to pressure, as it did just 36 months ago for 950 medicines
December 2, 2025 - - Latest News -
CLINUVEL advances second therapy toward market with planned 2026 European filing
December 2, 2025 - - Australian Biotech -
Burnt-Out Australians rush to health appointments as year-end pressure peaks
December 2, 2025 - - Other Health -
First patient successfully dosed in TRP-8803 trial to treat binge eating disorder
December 2, 2025 - - Australian Biotech -
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 - - Australian Biotech -
New national push to close Australia’s cardiovascular data gap
December 2, 2025 - - Latest News -
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News
